Literature DB >> 7201008

Erythropoietin levels in posterior fossa haemangioblastoma.

R V Jeffreys, J A Napier, S H Reynolds.   

Abstract

Using an in vitro bioassay, erythropoiesis stimulating activity has been measured in serum, cyst fluids and tumour homogenates from fourteen patients with cerebellar haemangioblastoma. Only two patients had elevated peripheral blood red cell counts and haemoglobin concentrations. Significantly elevated serum erythropoiesis stimulating activity was found in only one patient. High level, however, were detected in seven out of the fourteen cyst fluids and in the two homogenates tested. The dose response lines from these paralleled those of normal human erythropoietin. It was possible to neutralise the erythropoiesis stimulating activity in the cyst fluids with anti-human erythropoietin serum, indicating its similarity to erythropoietin, the normal erythropoietic regulating hormone. Significant release of the erythropoietic stimulating factor from the cyst fluids into the blood seemed to be an uncommon occurrence.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7201008      PMCID: PMC491350          DOI: 10.1136/jnnp.45.3.264

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  6 in total

1.  A COMPARISON OF SOME PHYSICAL AND CHEMICAL PROPERTIES OF ERYTHROPOIESIS-STIMULATING FACTORS FROM DIFFERENT SOURCES.

Authors:  W F ROSSE; T A WALDMANN
Journal:  Blood       Date:  1964-12       Impact factor: 22.113

2.  Some molecular characteristics of erythropoietin from different sources determined by inactivation ionizing radiation.

Authors:  W F ROSSE; R J BERRY; T A WALDMANN
Journal:  J Clin Invest       Date:  1963-01       Impact factor: 14.808

3.  The association of polycythemia with a cerebellar hemangioblastoma. The production of an erythropoiesis stimulating factor by the tumor.

Authors:  T A WALDMANN; E H LEVIN; M BALDWIN
Journal:  Am J Med       Date:  1961-08       Impact factor: 4.965

4.  Cerebellar hemangioma (hemangioblastoma); a clinicopathological review of 40 cases.

Authors:  M L SILVER; G HENNIGAR
Journal:  J Neurosurg       Date:  1952-09       Impact factor: 5.115

5.  Pathological and haematological aspects of posterior fossa haemangioblastomata.

Authors:  R Jeffreys
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-02       Impact factor: 10.154

6.  Erythropoietin assay using fetal mouse liver cell cultures: a modified technique using semi-automatic harvesting of I125 deoxyuridine labelled erythroblasts.

Authors:  J A Napier; J Evans
Journal:  Clin Lab Haematol       Date:  1980
  6 in total
  6 in total

1.  Erythropoietin in capillary hemangioblastoma. An immunohistochemical study.

Authors:  T Böhling; M Haltia; K Rosenlöf; F Fyhrquist
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

2.  Haemangioblastomas of the posterior cranial fossa.

Authors:  L Ferrante; P Celli; B Fraioli; A Santoro
Journal:  Acta Neurochir (Wien)       Date:  1984       Impact factor: 2.216

3.  Surgical management of haemangioblastoma of the posterior fossa.

Authors:  L Symon; T Murota; M Pell; L Bordi
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

4.  Histogenesis of haemangioblastomas: an immunocytochemical and ultrastructural study in a case of von Hippel-Lindau syndrome.

Authors:  S M Ismail; B Jasani; G Cole
Journal:  J Clin Pathol       Date:  1985-04       Impact factor: 3.411

5.  Loss of Quiescence in von Hippel-Lindau Hemangioblastomas is Associated with Erythropoietin Signaling.

Authors:  Michael J Feldman; Saman Sizdahkhani; Nancy A Edwards; Marsha J Merrill; Abhik Ray-Chaudhury; Zhengping Zhuang; Russell R Lonser; Edward H Oldfield; Prashant Chittiboina
Journal:  Sci Rep       Date:  2016-10-17       Impact factor: 4.379

6.  Polyglobulia in patients with hemangioblastomas is related to tumor size but not to serum erythropoietin.

Authors:  Marie T Krüger; Jan-Helge Klingler; Cordula Jilg; Christine Steiert; Stefan Zschiedrich; Vera Van Velthoven; Sven Gläsker
Journal:  Hered Cancer Clin Pract       Date:  2018-09-11       Impact factor: 2.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.